[Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

William J. Sibold, President, CEO and Director of Madrigal Pharmaceuticals, Inc. (MDGL), reported sales of company common stock on 08/21/2025 executed under a Rule 10b5-1 trading plan adopted on 11/15/2024. The filing shows an automated sale of 6,485 shares at a weighted-average price of $400.0347, after which the reporting person beneficially owned 110,884 shares. A subsequent automated sale of 1,131 shares at a weighted-average price of $401.0003 reduced beneficial ownership to 109,753 shares. The reporting person signed the Form 4 through an attorney-in-fact on 08/21/2025. All sales are disclosed as having been effected automatically pursuant to the specified 10b5-1 plan and the filing provides weighted-average price ranges for the transactions.

Insights

Financial Analyst

TL;DR: Insider executed scheduled sales under a 10b5-1 plan, disposing of 7,616 shares at ~ $400 each; disclosure is compliant and routine.

The Form 4 documents two automated stock sales by the company's President and CEO on 08/21/2025 under a 10b5-1 plan adopted 11/15/2024. The combined disposition of 7,616 shares occurred at weighted-average prices of $400.0347 and $401.0003. Beneficial ownership decreased from the pre-transaction level to 109,753 shares after the second sale. The filing includes weighted-average price ranges and offers to provide detailed per-price execution data on request, which supports transparency in execution details.

Corporate Governance Expert

TL;DR: Sales were effected pursuant to a pre-established 10b5-1 plan, indicating planned, rule-compliant insider dispositions.

The reporting person is identified as both President and CEO and a Director, and the Form 4 explicitly states the transactions were made automatically under a Rule 10b5-1 trading plan adopted on 11/15/2024. The filing is signed by an attorney-in-fact and provides explanatory footnotes on execution pricing ranges. From a governance perspective, the disclosure aligns with standard insider-trading compliance practices by documenting the plan date and offering detailed pricing information upon request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sibold William John

(Last) (First) (Middle)

C/O MADRIGAL PHARMACEUTICALS, INC.

200 BARR HARBOR DRIVE, SUITE 200

(Street)

WEST CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		S(1)		6,485	D	$400.0347(2)	110,884	D
Common Stock	08/21/2025		S(1)		1,131	D	$401.0003(3)	109,753	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $400.00 to $400.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnote below.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $401.00 to $401.01, inclusive.

Remarks:

	/s/ Mardi Dier, as Attorney-in-Fact	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.